CTRI/2023/09/057166招募中4 期
Effect of Pioglitazone vs Glimepiride on body composition and other parameters of adiposopathy in non-obese Asian Indian diabetics: A randomized open labeled parallel group comparative single centre study - NI
Professor and Head department of Endocrinology0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Newly diagnosed type-2 Diabetes Mellitus (ADA criteria) with BMI <30 kg/m2 and age > 18yrs 2. Type 2 diabetic patients with uncontrolled blood sugar (FBS >130, PPBS >180) on life-style intervention plus maximally tolerated dose of metformin
排除标准
- •Exclusion Criteria: 1. Patients with secondary Diabetes. 2. Patients with Type 1 Diabetes Mellitus. 3. Patients with latent autoimmune diabetes of adult. 4. Patient on insulin 5. Contraindication to pioglitazone (Active liver disease, NYHA Class 3 and 4 chf, CSME, hypersensitivity), metformin (severe renal impairment; egfr < 30mL/min/1.73m2, known hypersensitivity, acute or chronic metabolic acidosis including DKA) or glimepiride (known hypersensitivity, DKA, G6PD deficiency) 6. Pregnancy and lactation 7. Who refused for consent.
研究者
相似试验
已完成
不适用
Effect of pioglitazone in combination with glimepiride therapy on various parameters of insulin resistance including lipoprotein subclass levels in patients with type 2 diabetesJPRN-UMIN000002461Yamashiro Public Hospital50
进行中（未招募）
不适用
Effects of Pioglitazone in Combination with Glimepiride in Comparison to Glimepiride Monotherapy on Metabolic Control in Patients with Type 2 Diabetes mellitusEUCTR2006-002271-41-DETakeda Pharma GmbH
已完成
3 期
Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.Diabetes MellitusNCT00770952Takeda91
进行中（未招募）
不适用
Effect of Pioglitazone compared to a combination therapy with Ramipril and to a Ramipril monotherapy on low grade inflammation and vascular function in patients with increased cardiovascular risk and an activated inflammationA randomized double-blinded phase II studyon-diabetic hypertensive patients with a hsCRP value > 1.0 mg/L < 10.0 mg/L and pretreated with ACE inhibitors for at least 12 weeks are eligible for study participation.MedDRA version: 8.1Level: LLTClassification code 10003601Term: AtherosclerosisEUCTR2006-004028-35-DETakeda Pharma GmbH
已完成
不适用
Comparison of pioglitazone with sitagliptin effect in diabetes melitusdiabetes.E10-E14IRCT2016112631104N1Vice Chancellor for research of Lorestan University of Medical Sciences60